Pratt, Edward

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 478

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

Heise, T., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Thomas, M. K., Mather, K. J., Karanikas, C. A., Dunn, J., Haupt, A., et al. (2023) · Diabetes Care

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 208

Efficacy and safety of oral orforglipron in patients with type 2 diabetes: A multicentre, randomised, dose-response, phase 2 study

Frias, J. P., Hsia, S., Eyde, S., Liu, R., Ma, X., Konig, M., Kazda, C., Mather, K. J., Haupt, A., Pratt, E., et al. (2023) · The Lancet

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 184

Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation

Ravussin, E., Sanchez-Delgado, G., Martin, C. K., Beyl, R. A., Greenway, F. L., O’Farrell, L. S., Roell, W. C., Qian, H.-R., Li, J., Nishiyama, H., et al. (2025) · Cell Metabolism

Regulation of Appetite and ObesityPharmacology and Obesity Treatment

Cited by 72

Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants

Pratt, E., Ma, X., Liu, R., Robins, D., Haupt, A., Coskun, T., Sloop, K. W., & Benson, C. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 62

Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes

Pratt, E., Ma, X., Liu, R., Robins, D., Coskun, T., Sloop, K. W., Haupt, A., & Benson, C. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 60

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy

Knop, F. K., Urva, S., Rettiganti, M., Benson, C. T., Roell, W. C., Mather, K. J., Haupt, A., & Pratt, E. J. (2024) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 41

Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist

Ma, X., Liu, R., Pratt, E. J., Benson, C. T., Bhattachar, S. N., & Sloop, K. W. (2024) · Diabetes Therapy

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 38

Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test

Mather, K. J., Mari, A., Heise, T., DeVries, J. H., Hua, M., Urva, S., Coskun, T., Haupt, A., Heine, R. J., Pratt, E., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 35

56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting

KNOP, F. K., URVA, S., RETTIGANTI, M., BENSON, C., ROELL, W., MATHER, K. J., HAUPT, A., & PRATT, E. J. (2023) · Diabetes

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 29

128-OR: The Effect of Tirzepatide during Weight Loss on Food Intake, Appetite, Food Preference, and Food Craving in People with Obesity

MARTIN, C. K., RAVUSSIN, E., SANCHEZ-DELGADO, G., NISHIYAMA, H., LI, J., URVA, S., PRATT, E. J., MILICEVIC, Z., HAUPT, A., & COSKUN, T. (2023) · Diabetes

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 21